To direct the Comptroller General of the United States to conduct a study to assess the key regulatory barriers that impede the expansion or siting of new pharmaceutical manufacturing facilities in the United States, and for other purposes.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill directs the Government Accountability Office (GAO) to study regulatory barriers preventing pharmaceutical manufacturing expansion in the United States and to recommend streamlining measures. It relies on reporting requirements. The main policy areas are Healthcare and Trade.
Who Benefits and How
Pharmaceutical manufacturers could face lower compliance burdens.
Who Bears the Burden and How
Government Accountability Office (GAO) would take on compliance duties.
Key Provisions
- Directs the Government Accountability Office (GAO) to study regulatory barriers preventing pharmaceutical manufacturing expansion in the United States and to recommend streamlining measures.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill directs the Government Accountability Office (GAO) to study regulatory barriers preventing pharmaceutical manufacturing expansion in the United States and to recommend streamlining measures.
Key Policy Areas
Healthcare, Trade
Primary Purpose
The bill directs the Government Accountability Office (GAO) to study regulatory barriers preventing pharmaceutical manufacturing expansion in the United States and to recommend streamlining measures.
Policy Domains
Title I — Study on Key Regulatory Barriers
Identified Gains
- Pharmaceutical manufacturers
Identified Costs
- Government Accountability Office (GAO)
Sponsors
Legislative Progress
IntroducedMr. Buchanan (for himself and Mr. Donalds) introduced the following …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_comptroller_general"
- → Comptroller General of the United States
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology